文献速递系统性红斑狼疮

优化羟氯喹血药浓度与长期摄入可降低SLE患者动脉粥样硬化性心血管疾病风险并预防多重用药

Optimizing Hydroxychloroquine Blood Levels and Long-Term Hydroxychloroquine Intake Could Lower Atherosclerotic Cardiovascular Disease Risk and Prevent Polypharmacy in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-08-03

该前瞻性纵向研究纳入248例符合2019年ACR/EULAR标准的SLE成人患者,评估羟氯喹血药浓度与长期摄入模式与基线及一年后预估ASCVD风险的关系。结果发现,极低羟氯喹血药浓度(<200 ng/mL)和低长期摄入(PDC<80%)者基线ASCVD风险显著更高(+2.1%),平均预测风险为6.6%;持续处于或转入低暴露类别者随访时ASCVD风险最高(5.7%)。结论认为维持低长期摄入和极低血药浓度增加ASCVD风险,促进持续依从和治疗性血药浓度或可改善心血管结局。

要点

  • 极低羟氯喹血药浓度(<200 ng/mL)与低长期摄入(PDC<80%)者基线ASCVD风险增加2.1%。
  • 持续处于或转入低暴露类别者随访时ASCVD风险最高,达5.7%。
  • 促进持续依从和治疗性羟氯喹血药浓度或可改善心血管结局并减少不必要预防治疗。

核心结论

  • 维持低长期羟氯喹摄入和极低羟氯喹血药浓度会增加SLE患者的ASCVD风险。

研究设计与样本

  • 前瞻性纵向研究,纳入248例来自Wisconsin队列、符合2019年ACR/EULAR标准、服用羟氯喹并完成基线和一年随访的SLE成人患者。
  • 长期羟氯喹摄入用比例覆盖天数(PDC)估算,全血羟氯喹浓度作为近期暴露标志物。

主要发现

  • 极低羟氯喹血药浓度(<200 ng/mL)和低长期摄入(PDC<80%)者基线ASCVD风险显著更高(+2.1%),平均预测风险为6.6%。
  • 持续处于或转入低暴露类别者随访时ASCVD风险最高(5.7%)。

关键数值与推荐

  • 极低羟氯喹血药浓度定义为<200 ng/mL。
  • 低长期摄入定义为PDC<80%。

临床怎么用

  • 临床应关注SLE患者羟氯喹长期依从性(PDC≥80%)和血药浓度(≥200 ng/mL),以降低ASCVD风险。
  • 对持续低暴露患者,可考虑干预促进依从和治疗性血药浓度,并评估心血管预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hydroxychloroquine (HCQ) is the cornerstone of systemic lupus erythematosus (SLE) management with benefits extending beyond SLE control, including protection against atherosclerotic cardiovascular disease (ASCVD). Although HCQ blood levels reflect recent exposure and long-term intake reflects medication adherence, the impact of longitudinal changes in both measures on ASCVD risk over time remains unclear. We evaluated how HCQ blood levels and long-term intake patterns relate to estimated ASCVD risk at baseline and after one year. METHODS: In this prospective longitudinal study, 248 adults with SLE from the Wisconsin cohort (meeting 2019 American College of Rheumatology/EULAR criteria) taking HCQ and completing baseline and one-year follow-up visits were included. Long-term HCQ intake was estimated using the proportion of days covered (PDC), and whole-blood HCQ levels served as a marker of recent exposure. Ten-year ASCVD risk was calculated at both time points using the PREVENT calculator. Multivariable linear regression assessed associations between HCQ exposure patterns and ASCVD risk. Changes in exposure categories over one year were also evaluated. RESULTS: Patients with very low HCQ blood levels (<200 ng/mL) and low long-term intake (PDC <80%) had significantly higher ASCVD risk at baseline (+2.1%) with a mean predicted risk of 6.6%. Those who remained in or transitioned into these low-exposure categories over one year had the highest ASCVD risk at follow-up (5.7%). CONCLUSION: Maintaining low long-term HCQ intake and very low HCQ blood levels increased ASCVD risk in patients with SLE. Interventions promoting sustained adherence and therapeutic HCQ levels may enhance cardiovascular outcomes and reduce unnecessary preventive therapies.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Garg S, Urowitz M, Dentz C, et al. Optimizing Hydroxychloroquine Blood Levels and Long-Term Hydroxychloroquine Intake Could Lower Atherosclerotic Cardiovascular Disease Risk and Prevent Polypharmacy in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2026. PMID: 42544859. doi:10.1002/acr.80128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。